Best Practice & Research Clinical Rheumatology
Volume 24, Issue 4 , Pages 541-552, August 2010

Prospects for gene therapy in inflammatory arthritis

  • Christian Jorgensen, MD, PhD (Professor, Head of clinical department and of inserm unit U 844)

      Affiliations

    • Inserm, U844, Montpellier, F-34091 France
    • Université MONTPELLIER 1, UFR de Médecine, Montpellier, F-34000 France
    • Service d'immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, F-34295 France
    • Corresponding Author InformationCorresponding author. Inserm U844, CHU Saint Eloi, Bâtiment INM, 80 avenue Augustin Fliche Montpellier F-34295, France. Tel.: +33 4 99 63 60 26; Fax: +33 4 99 63 60 20.
  • ,
  • Florence Apparailly, PhD (Senior Researcher CR1 inserm)

      Affiliations

    • Inserm, U844, Montpellier, F-34091 France
    • Université MONTPELLIER 1, UFR de Médecine, Montpellier, F-34000 France
    • Service d'immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, F-34295 France

Gene therapy holds great promise for the treatment of rheumatoid arthritis (RA). In this article, we focus on innovation in vector, promoter or target genes. Gene therapy is defined as an introduction of nucleic acids into a host cell for therapeutic purposes; the option may be the overexpression of therapeutic gene or an underexpression of a target gene highly expressed in disease (small interfering RNA (siRNA)). The proof of principle in animal models of arthritis has shown convincingly that gene therapy can be an advantageous strategy in the treatment of RA. A gene therapy approach is advantageous over biologics for joint-specific targeting and long-term expression of an anti-arthritic molecule, replacing the frequent administration of recombinant proteins. We also discuss the currently used gene therapy clinical trials and define optimal strategies for success.

Keywords: gene therapy, vectors, arthritis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6942(10)00011-2

doi:10.1016/j.berh.2010.02.001

Best Practice & Research Clinical Rheumatology
Volume 24, Issue 4 , Pages 541-552, August 2010